Role of corticosteroid treatment in progression of respiratory viral illnesses
| Virus . | Progression . | Mortality . | ||||||
|---|---|---|---|---|---|---|---|---|
| Steroid dose per day . | Risk . | HR (95% CI) . | P value . | Steroid dose per day . | Risk . | HR (95% CI) . | P value . | |
| RSV | >2 mg/kg | +/− | 1.4 (0.4-5.2) | .193 | >2 mg/kg | + + + | 3.3 (1.7-6.3) | <.00111 |
| Influenza | ≥1 mg/kg | +/− | 0.8 (0.2-2.4) | .6045 | ≥1 mg/kg | +/− | 1.1 (0.3-3.5) | .8745 |
| PIV | >2 mg/kg | + + + | 4.6 (1.2-17.0) | .0274 | >2 mg/kg | + + + | 3.2 (1.5-7.2) | .00413 |
| HMPV or RSV | Not reported in the combined cohort | Any steroids | + + + | 5.0 (1.8-14) | .00216 | |||
| ≥1 mg/kg | + + + + | 7.1 (2.3-22) | <.00116 | |||||
| Virus . | Progression . | Mortality . | ||||||
|---|---|---|---|---|---|---|---|---|
| Steroid dose per day . | Risk . | HR (95% CI) . | P value . | Steroid dose per day . | Risk . | HR (95% CI) . | P value . | |
| RSV | >2 mg/kg | +/− | 1.4 (0.4-5.2) | .193 | >2 mg/kg | + + + | 3.3 (1.7-6.3) | <.00111 |
| Influenza | ≥1 mg/kg | +/− | 0.8 (0.2-2.4) | .6045 | ≥1 mg/kg | +/− | 1.1 (0.3-3.5) | .8745 |
| PIV | >2 mg/kg | + + + | 4.6 (1.2-17.0) | .0274 | >2 mg/kg | + + + | 3.2 (1.5-7.2) | .00413 |
| HMPV or RSV | Not reported in the combined cohort | Any steroids | + + + | 5.0 (1.8-14) | .00216 | |||
| ≥1 mg/kg | + + + + | 7.1 (2.3-22) | <.00116 | |||||
CI, confidence interval; HR, hazard ratio.